

To: CN=Neil W Aubuchon/OU=AP/O=LLY@Lilly
CC: CN=Matthew R Pike/OU=AM/O=LLY@Lilly; CN=Michael E Bandick/OU=AM/O=LLY@Lilly
Date: 11/20/2002 10:51:14 AM
From: CN=Bin Gu/OU=AM/O=LLY
Subject: Re: Request

Neil,
Thanks for the good questions. Could I suggest we have a conference call to discuss this. I would suggest either this Thursday 6-7:00pm (Indy time)=Friday 8-9:00am (Japan time) or early next week . Please let us know your choice so I can arrange it. Thanks!

Also I forward Diabetes position paper (in case you haven't) for the discussion.

Gu,Bin
(317) 277-6483

Neil W Aubuchon

11/19/2002 07:14 PM

To: Bin Gu/AM/LLY@Lilly
cc: Matthew R Pike/AM/LLY@Lilly, Michael E Bandick/AM/LLY@Lilly
Subject: Re: Request

Bin,

Thanks for staying late and promptly answering our question. It is very helpful.

Let me ask you two follow-ups:

1) What is the strategy regarding diabetes? Are we trying to show through retrospective studies that it isn't that big of a problem? I understand that we are trying to neutralize the issue, but how are we trying to do that?

2) If you could provide (even informally) the key results of the hyperglycemia/diabetes publications that have been submitted that would be

Page: 1 of 4

extremely useful.

Just so I can give you some context, we had a large symposium this past weekend and the first question after we give our talk is `why does Zyprexa occassionally cause hyperglycemia?` We cannot say it doesn't cause hyperglycemia because of our label here. Our answer is `we don't know, but it is a very rare problem and if you use it and follow the Dr. Fuji guidelines (Blood glucose monitoring) you can feel confident to use it safely. That is where we are at now.

Regards, Neil

Bin Gu

2002/11/20 08:52

To: Matthew R Pike/AM/LLY@Lilly
cc: Michael E Bandick/AM/LLY@Lilly, Neil W Aubuchon/AP/LLY@Lilly
Subject: Re: Request

Neil,

Please find attached file of safety publication overview for your reference . It includes the studies that have been published and are going to be published on safety issue (weight gain,hyperglycemia/diabetes and lipid). Hope it can meet your need. Any question, please let me know.
Thanks!

Gu,Bin
(317) 277-6483

Matthew R Pike

11/19/2002 05:55 PM

To: Neil W Aubuchon/AP/LLY@Lilly
cc: Michael E Bandick/AM/LLY@Lilly, Bin Gu/AM/LLY@Lilly
Subject: Re: Request

Page: 2 of 4

Neil,

Gu Bin can accomodate your request as it relates to metabolic issues.

Matt Pike, R.Ph.
Issues Management Manager
Zyprexa Global Marketing
317-651-3990

Neil W Aubuchon

11/19/2002 05:28 PM

To: Matthew R Pike/AM/LLY@Lilly
cc: Michael E Bandick/AM/LLY@Lilly
Subject: Request

Matt,

I have attached a word file that was sent to the policy committee regarding the diabetes issue. In the document there is discussion of various epidemiological studies etc. that are being conducted on the issue. We are struggling to develop our own clinical trials (as well as handle IIT requests) and think that getting any background info on the global activities would be helpful. Who is the best person to contact? Is it Patricia?

Thanks in advance.

regards, Neil

[attachment "Policy Cmte Pre-Read on Diab - Sept 02.doc" has been removed by Bin Gu/AM/LLY]

Page: 3 of 4

[attachment "safety publication overview(Nov02).xls" has been removed by Bin Gu/AM/LLY]